Market Capitalisation is a Better Valuation Metric Than Share Price, page-95

First 95 Last

Share
Profile

Follow
Tony barber

6,294 Posts.

670

30/12/23

23:06

Post #: 71671798
Share
Originally posted by Agent-86 ↑

Ha Ha ... my post really seems to have stirred the nest.

To be quite frank, I was getting a little tired of the many people posting that they would jump at $50 if it was on the table tomorrow.

My post was really to demonstrate one practical model that would result in a share price above $50.
As you can see in my model the end game was for a Big Pharma to take out both NEU and Acadia in a step phase process, with at each stage a 1.5 times moderate uplift. Quite a reasonable model without getting too carried away.

My goals are very simple and have always been that way when I invest in biotech companies more than any other industry:

I really like investing in companies where the outcomes provide goodness to people - those suffering, their families and care givers

The biotech companies have a strong Board, Senior Mgt Team, Researchers & Advisory Team that "do what they say they will do"

The companies stay true to its goals and continues to deliver whilst dealing with the challenges along the way in their stride

A company that respects it target audience (patients) and the wide variety of shareholders - maximises $$$$ spent on its programs

Delivers the outcomes with modesty and pride.

For me, my investment in NEU in reflected in these statements.

I really don't mind who takes control of NEU as long as they show a similar dedication to the cause of improving the lives of those suffering.

Wonderful year in 2023 and I am confident the good news will continue into an exciting 2024 and beyond.

Happy New Year

GLTA

Expand

Not sure if your post is referring to me.
But I don't read your long form posts. Just the first two lines.

Ive seen you on other stocks. Just not worth the time sorry.
NEU Price at posting: $24.97 Sentiment: Buy Disclosure: Held
3 Upvote

0 Great analysis

Reply